BR112018016301A2 - tecnologia não-invasiva de inserto ocular para libertação controlada de fármacos - Google Patents

tecnologia não-invasiva de inserto ocular para libertação controlada de fármacos

Info

Publication number
BR112018016301A2
BR112018016301A2 BR112018016301-5A BR112018016301A BR112018016301A2 BR 112018016301 A2 BR112018016301 A2 BR 112018016301A2 BR 112018016301 A BR112018016301 A BR 112018016301A BR 112018016301 A2 BR112018016301 A2 BR 112018016301A2
Authority
BR
Brazil
Prior art keywords
drug
insert
eye
release
eye insert
Prior art date
Application number
BR112018016301-5A
Other languages
English (en)
Inventor
João Mota Leite Machado Mariz Marcos
Cristina Nunes Ferreira Calvinho Paula
Helena Mendes Gil Maria
Carlos Neto Murta Joaquim
Original Assignee
Universidade De Coimbra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidade De Coimbra filed Critical Universidade De Coimbra
Publication of BR112018016301A2 publication Critical patent/BR112018016301A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29D—PRODUCING PARTICULAR ARTICLES FROM PLASTICS OR FROM SUBSTANCES IN A PLASTIC STATE
    • B29D11/00—Producing optical elements, e.g. lenses or prisms
    • B29D11/02—Artificial eyes from organic plastic material
    • B29D11/023—Implants for natural eyes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29D—PRODUCING PARTICULAR ARTICLES FROM PLASTICS OR FROM SUBSTANCES IN A PLASTIC STATE
    • B29D11/00—Producing optical elements, e.g. lenses or prisms
    • B29D11/00009—Production of simple or compound lenses
    • B29D11/00038—Production of contact lenses
    • B29D11/00096—Production of contact lenses for delivering compositions, e.g. drugs to the eye
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2067/00—Use of polyesters or derivatives thereof, as moulding material
    • B29K2067/04—Polyesters derived from hydroxycarboxylic acids
    • B29K2067/046—PLA, i.e. polylactic acid or polylactide
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2071/00—Use of polyethers, e.g. PEEK, i.e. polyether-etherketone or PEK, i.e. polyetherketone or derivatives thereof, as moulding material
    • B29K2071/02—Polyalkylene oxides, e.g. PEO, i.e. polyethylene oxide, or derivatives thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/0005—Condition, form or state of moulded material or of the material to be shaped containing compounding ingredients
    • B29K2105/0035—Medical or pharmaceutical agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/0085—Copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Mechanical Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a invenção refere-se a um inserto ocular biocompatível e com composição polimérica, concebido para a libertação prolongada de fármacos no tratamento de diferentes patologias oculares. este inserto ocular permite a libertação de pelo menos um fármaco em níveis de concentração adequados durante períodos de tempo prédeterminados. o dispositivo pode ser inserido na fórnice conjuntival (superior ou inferior), de forma não invasiva, (figura 1), o que significa que o paciente será capaz de colocar o dispositivo sozinho, sem intervenção de pessoal médico especializado. o inserto ocular objeto desta invenção permitirá a libertação do fármaco de uma forma tão controlada que este processo poderá decorrer em períodos de tempo até 300 dias sob um perfil ?fickiano? ou linear de acordo com a finalidade/patologia que se pretende tratar. o inserto pode ser preparado com formas (esféricas ou hemisféricas) e/ou arquitecturas (monolíticas/em camadas com ou sem um núcleo de fármaco) diferentes, permitindo a incorporação de pelo menos um fármaco e que podem ser libertados a taxas diferentes. o tamanho, a forma e o desenho do inserto são adaptados de modo a ajustar o(s) perfil(s) de distribuição do fármaco e reduzir o risco de deslocamento ou expulsão.
BR112018016301-5A 2016-02-12 2017-02-10 tecnologia não-invasiva de inserto ocular para libertação controlada de fármacos BR112018016301A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PT109154 2016-02-12
PT109154A PT109154B (pt) 2016-02-12 2016-02-12 Tecnologia não-invasiva de inserto ocular para libertação controlada de fármacos
PCT/IB2017/050731 WO2017137934A1 (en) 2016-02-12 2017-02-10 Non-invasive ocular drug delivery insert technology

Publications (1)

Publication Number Publication Date
BR112018016301A2 true BR112018016301A2 (pt) 2018-12-26

Family

ID=58428316

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018016301-5A BR112018016301A2 (pt) 2016-02-12 2017-02-10 tecnologia não-invasiva de inserto ocular para libertação controlada de fármacos

Country Status (10)

Country Link
US (1) US11642311B2 (pt)
EP (1) EP3413872A1 (pt)
JP (1) JP2019504855A (pt)
AU (1) AU2017217358B2 (pt)
BR (1) BR112018016301A2 (pt)
CA (1) CA3013878A1 (pt)
PT (1) PT109154B (pt)
RU (1) RU2749426C2 (pt)
SG (1) SG11201806625WA (pt)
WO (1) WO2017137934A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3801462A4 (en) 2018-05-24 2022-03-16 Celanese EVA Performance Polymers LLC IMPLANTABLE DEVICE FOR EXTENDED RELEASE OF A MACROMOLECULAR DRUG COMPOUND
KR20210013089A (ko) 2018-05-24 2021-02-03 셀라니즈 이브이에이 퍼포먼스 폴리머스 엘엘씨 거대 분자 약물 화합물의 지속적인 방출을 위한 이식가능 장치
CN114340690B (zh) 2019-06-27 2023-11-03 雷尔生物公司 眼部装置递送方法和系统
CN114727954A (zh) 2019-09-18 2022-07-08 爱尔康公司 湿包装的软水凝胶眼睛插入物
CN113057794B (zh) * 2019-12-31 2023-03-10 财团法人工业技术研究院 眼用药物输送装置及其制备方法
WO2022056392A1 (en) * 2020-09-14 2022-03-17 EyePoint Pharmaceuticals, Inc. Bioerodible ocular drug delivery insert and therapeutic method
CN112618480B (zh) * 2020-11-10 2022-07-12 南昌大学 一种眼部药物递送体系的制备方法
EP4259689A1 (en) * 2020-12-11 2023-10-18 F. Hoffmann-La Roche AG Novel polymers and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993071A (en) * 1971-09-09 1976-11-23 Alza Corporation Bioerodible ocular device
US4438123A (en) 1980-03-04 1984-03-20 Merck & Co., Inc. Ophthalmic compositions of carbonic anhydrase inhibitors for topical application in the treatment of elevated intraocular pressure
US4668506A (en) 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
US4931279A (en) 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
US4713244A (en) 1985-08-16 1987-12-15 Bausch & Lomb Incorporated Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
US5137728A (en) * 1988-03-01 1992-08-11 Bausch & Lomb Incorporated Ophthalmic article
RU2014813C1 (ru) * 1992-07-03 1994-06-30 Фирма "Токем" Способ изготовления вкладыша для лечения химических ожогов глаз
RU2100020C1 (ru) * 1993-06-23 1997-12-27 Лейрас Ой Средство для местного лечения глазной гипертензии и глаукомы и способ его получения
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6217896B1 (en) * 1999-04-01 2001-04-17 Uab Research Foundation Conjunctival inserts for topical delivery of medication or lubrication
US6468543B1 (en) 1999-05-03 2002-10-22 Zymogenetics, Inc. Methods for promoting growth of bone using ZVEGF4
FR2795326B1 (fr) * 1999-06-28 2001-08-31 Adir Composition pharmaceutique solide thermoformable a liberation controlee
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
WO2002045695A2 (en) * 2000-12-05 2002-06-13 Alexander Macgregor Hydrostatic delivery system for controlled delivery of agent
NZ540885A (en) 2002-12-20 2009-02-28 Chakshu Res Inc Ophthalmic formulation for the prevention and treatment of ocular conditions
US8685435B2 (en) * 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US7799336B2 (en) * 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US7320690B2 (en) * 2004-05-13 2008-01-22 Biocoat Incorporated IOL insertion device with lubricious coating
US20060024350A1 (en) * 2004-06-24 2006-02-02 Varner Signe E Biodegradable ocular devices, methods and systems
JP5081413B2 (ja) * 2005-07-29 2012-11-28 参天製薬株式会社 固形組成物を用いた後眼部組織への非侵襲性ドラッグデリバリーシステム
US9693967B2 (en) * 2005-09-07 2017-07-04 Southwest Research Institute Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates
US8586556B2 (en) * 2006-11-03 2013-11-19 Allergan, Inc. Methods, compositions and drug delivery systems for intraocular delivery of siRNA molecules
TR200708925A1 (tr) * 2007-12-26 2009-07-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Kontrollü salım sağlayan flurbiprofen ve kas gevşetici kombinasyonları
EP3320892A1 (en) * 2010-01-22 2018-05-16 Allergan, Inc. Intracameral sustained release therapeutic agent implants
AU2011227289B2 (en) * 2010-03-16 2016-01-21 Titan Pharmaceuticals, Inc. Heterogeneous implantable devices for drug delivery
US8821457B2 (en) 2010-09-08 2014-09-02 Johnson & Johnson Vision Care, Inc. Punctal plug containing drug formulation
US20120215184A1 (en) * 2011-02-18 2012-08-23 Valeant International (Barbados) Srl Cylindrical ocular inserts

Also Published As

Publication number Publication date
US11642311B2 (en) 2023-05-09
PT109154B (pt) 2019-11-05
AU2017217358A1 (en) 2018-08-30
JP2019504855A (ja) 2019-02-21
WO2017137934A1 (en) 2017-08-17
US20190046434A1 (en) 2019-02-14
RU2749426C2 (ru) 2021-06-10
EP3413872A1 (en) 2018-12-19
RU2018128943A (ru) 2020-03-12
AU2017217358B2 (en) 2022-09-29
PT109154A (pt) 2017-08-14
RU2018128943A3 (pt) 2020-06-01
CA3013878A1 (en) 2017-08-17
SG11201806625WA (en) 2018-09-27

Similar Documents

Publication Publication Date Title
BR112018016301A2 (pt) tecnologia não-invasiva de inserto ocular para libertação controlada de fármacos
MX2021004546A (es) Composiciones de suministro de farmaco implantables y metodos de uso de las mismas.
EP3861982A3 (en) Intracameral implant for treatment of an ocular condition
BR112012025581A2 (pt) implantes de reservatório de liberação sustentada para distribuição de fármaco intracameral
BRPI0510439A (pt) implantes intraoculares de liberação sustentada contendo macromoléculas e métodos relacionados
PH12017501097A1 (en) Sunitinib formulations and methods for use thereof in treatment of ocular disorders
BR112019005351A2 (pt) terapia combinada com agonistas de cnp de liberação controlada
EP2113264A3 (de) Implantat umfassend eine Oberfläche mit verringerter Thrombogenität
EP3545948A4 (en) APPLICATION OF GOLD AGGREGATE OR GOLD AGGREGATE SUBSTANCE FOR THE PREPARATION OF A MEDICINE INDICATED FOR PROPHYLAXIS AND / OR THE TREATMENT OF GLAUCOMA
WO2009059055A3 (en) Method of making a vascular closure device
AR064078A1 (es) Sistema de administracion de farmacos intraocular inyectable biocompatible, su uso para preparar un medicamento y proceso para su preparacion
EP3300734A3 (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders
AR088585A1 (es) Un medicamento para tratar la enfermedad del ojo anterior
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
WO2014210315A3 (en) Stents and methods of use thereof
BR112021017436A2 (pt) Composições farmacêuticas para tratamento de doenças ou transtornos oculares
WO2016060917A3 (en) Formulations for histatin therapeutics
EP3590338A3 (en) Medical treatments based on anamorelin
BR112015011294A2 (pt) nanopartículas com polímero biodegradável e biocompatível plga carregadas com o fármaco de uso humano pentoxifilina
EP3952922A4 (en) TREATMENT OF LYSOSOMAL STORAGE DISEASE IN THE EYE BY ADMINISTRATION OF TPP1-EXPRESSING AAVS
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
MX2022002306A (es) Metodos de tratamiento de enfermedades oculares con un implante para la administracion sostenida de farmacos.
Kurganova et al. A role of melatonin in the treatment of low back pain
WO2014182696A3 (en) Bioresorbable scaffold for neurologic drug delivery
Lee Case reports on 70 Tic disorder cases managed with functional cerebrospinal therapy (FCST)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]